{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:57Z","timestamp":1791328917104,"version":"4.3.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T00:00:00Z","timestamp":1274659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]. Efficacy of these agents was also shown when they were administered to patients with left ventricular dysfunction and signs and symptoms of CHF early after acute myocardial infarction. It is not known whether the selective aldosterone antagonist eplerenone can improve outcomes in mildly symptomatic patients. The Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF) was designed to evaluate the effect of eplerenone on mortality and morbidity in patients with chronic systolic HF in NYHA class II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Approximately 3100 patients with ejection fraction \u226430% and estimated glomerular filtration rate \u226530 mL\/min\/1.73 m2 will be recruited. Patients are randomized 1:1 to double-blind eplerenone or placebo in addition to standard chronic HF therapy. Doses are adjusted from 25 mg every other day to 50 mg daily, depending on serum potassium. The primary endpoint is a composite of time to cardiovascular death or first hospital admission for worsening HF, whichever occurs first.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study will be complete when approximately 813 subjects experience a primary endpoint.<\/jats:p>\n                    <jats:p>Clinical Trials.gov. NCT00232180.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfq049","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T20:40:22Z","timestamp":1271191222000},"page":"617-622","source":"Crossref","is-referenced-by-count":73,"title":["Rationale and Design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)"],"prefix":"10.1093","volume":"12","author":[{"given":"Faiez","family":"Zannad","sequence":"first","affiliation":[{"name":"Inserm, Centre d'Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Drexler","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Centre, University Medical Centre , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Shi","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,5,24]]},"reference":[{"key":"2026020203340861500_ejhfhfq049-bib-0001","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"2026020203340861500_ejhfhfq049-bib-0002","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026020203340861500_ejhfhfq049-bib-0003","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"2026020203340861500_ejhfhfq049-bib-0004","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1006\/jmcc.2002.2088","article-title":"Molecular mechanisms of myocardial remodeling. The role of aldosterone","volume":"34","author":"Delcayre","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"2026020203340861500_ejhfhfq049-bib-0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0006","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"2026020203340861500_ejhfhfq049-bib-0007","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9149(03)00658-1","article-title":"Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure","volume":"92","author":"Fung","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026020203340861500_ejhfhfq049-bib-0008","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"2026020203340861500_ejhfhfq049-bib-0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2459\/JCM.0b013e3281053a9a","article-title":"Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)","volume":"8","author":"Boccanelli","year":"2007","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026020203340861500_ejhfhfq049-bib-0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/01.CIR.0000091234.45664.62","article-title":"Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial","volume":"108","author":"Cohn","year":"2003","journal-title":"Circulation"},{"key":"2026020203340861500_ejhfhfq049-bib-0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020203340861500_ejhfhfq049-bib-0012","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020203340861500_ejhfhfq049-bib-0013","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0014","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026020203340861500_ejhfhfq049-bib-0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","article-title":"Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J Card Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1185\/030079906X80233","article-title":"The effect of neurohormonal antagonists in reducing heart failure hospitalizations","volume":"22","author":"Williams","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2026020203340861500_ejhfhfq049-bib-0017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions The SOLVD Investigators","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"2026020203340861500_ejhfhfq049-bib-0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/eurjhf\/hfp025","article-title":"Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics","volume":"11","author":"Gustafsson","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0019","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026020203340861500_ejhfhfq049-bib-0020","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1001\/jama.299.22.2656","article-title":"Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction","volume":"299","author":"Wang","year":"2008","journal-title":"JAMA"},{"key":"2026020203340861500_ejhfhfq049-bib-0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0022","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020203340861500_ejhfhfq049-bib-0023","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejheart.2006.10.005","article-title":"Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker","volume":"9","author":"Berry","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0024","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"2026020203340861500_ejhfhfq049-bib-0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"2026020203340861500_ejhfhfq049-bib-0026","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","author":"Udelson","journal-title":"Cir Heart Fail"},{"key":"2026020203340861500_ejhfhfq049-bib-0027","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020203340861500_ejhfhfq049-bib-0028","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203340861500_ejhfhfq049-bib-0029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejheart.2007.12.006","article-title":"Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial","volume":"10","author":"Weir","year":"2008","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfq049","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/6\/617\/66522366\/eurjhf_12_6_617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/6\/617\/66522366\/eurjhf_12_6_617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:34:16Z","timestamp":1770021256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/12\/6\/617\/8435871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,24]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,5,24]]},"published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfq049","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,6]]},"published":{"date-parts":[[2010,5,24]]}}}